Artículos del autor

solaci

Day 3

ENGAGE AF-TIMI 48: Endoxaban versus warfarin in atrial fibrillation

The endoxaban is an oral direct inhibitor of factor Xa with a rapid onset of action and...
solaci -
Day 3

EU-PACT: Warfarin dose guided by genotype

Anticoagulation level in response to a fixed dose of warfarin is difficult to predict at the start...
solaci -
Day 3

RADAR AF: High-frequency ablation versus pulmonary vein isolation to treat atrial fibrillation

Atrial fibrillation is initiated by focal triggers and maintained by an atrial substrate called fractioned complex of...
solaci -
Day 3

ERASE: Endovascular treatment plus exercise versus exercise alone to treat claudication

Initial therapy for intermittent claudication has been historically the gear train, however, especially in recent years; the...
solaci -
Day 1

NIAMI: Nitroprusside infusion prior to primary angioplasty

The phenomenon of reperfusion injury is responsible for 50 % of the final infarct size. Several pharmacological...
solaci -
Day 1

TTM: Hypothermia after cardiac arrest does not offer benefits

Previous studies evaluated therapeutic hypothermia (32 ° C to 34 ° C for 12-24 hours) in patients...
solaci -
Day 1

Mild hypothermia in pre-hospital phase after cardiac arrest

Hypothermia in the hospital phase at 32-34 ° C improves neurological outcome in patients resuscitated after ventricular...
solaci -
Day 2

Promoting cardiovascular health in the preschool age

Cardiovascular disease is the worldwide leading cause of death. Changes in lifestyle, diet and sedentary routine have...
solaci -